None approved for ASO; Growth hormone therapy used for symptom management
Prader-Willi syndrome (PWS) is a complex genetic disorder caused by loss of function of genes on chromosome 15q11.2–13 that are normally expressed only from the paternal allele. The maternal copies of these genes are epigenetically silenced by genomic imprinting. When the paternal copies are deleted, disrupted, or absent (through maternal uniparental disomy), there is no expression of these critical genes.
PWS is characterized by severe hypotonia and feeding difficulties in infancy, followed by the development of insatiable appetite (hyperphagia) and obesity beginning in early childhood. Additional features include short stature, hypogonadism, intellectual disability, behavioral problems (including tantrums and obsessive-compulsive features), and a distinctive facial appearance. The hyperphagia is the most medically dangerous feature, as uncontrolled eating can lead to morbid obesity and its complications.
The 15q11.2–13 region contains several genes that are paternally expressed and maternally silenced, including SNRPN (small nuclear ribonucleoprotein polypeptide N), MAGEL2, NDN, and a cluster of small nucleolar RNAs (snoRNAs, particularly the SNORD116 cluster). Loss of the SNORD116 cluster is thought to be the primary driver of the PWS phenotype, particularly the hyperphagia.
The maternal copies of these genes are present and structurally intact in most PWS patients but are silenced by an imprinting center that directs DNA methylation and heterochromatin formation on the maternal allele. This creates a therapeutic opportunity analogous to Angelman syndrome: an ASO could potentially be designed to disrupt the silencing mechanism and reactivate expression of the maternal copies.
ASO approaches for PWS are in preclinical research stages. Potential strategies include targeting the regulatory RNAs or transcripts that maintain maternal silencing, disrupting the antisense transcripts that enforce imprinting, or targeting specific epigenetic regulatory elements. The complexity of the imprinted region, with multiple genes and regulatory elements, makes this a challenging but scientifically important target.
Current treatment for PWS focuses on symptom management: growth hormone therapy (which improves height, body composition, and muscle tone), strict dietary supervision to manage hyperphagia, behavioral interventions, and hormone replacement therapy for hypogonadism. These treatments improve quality of life but do not address the underlying genetic cause.
Pequliar designs ASO candidates for Prader-Willi syndrome, exploring strategies to reactivate the silenced maternal alleles. The platform identifies potential target sites in the regulatory region, designs and scores antisense sequences, and provides synthesis-ready specifications for preclinical research and evaluation.
Describe your mutation and get ranked, synthesis-ready ASO candidates in minutes. $399 per design.
Start a designPequliar is a computational research tool for informational purposes only. All sequences are computationally predicted candidates that have not been experimentally validated. Pequliar does not prescribe, recommend, or administer any compound. Independent validation by qualified professionals is required.